Alnylam Pharmaceuticals, Inc.
ALNY · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $59,940 | $42,286 | $35,015 | $30,259 |
| - Cash | $1,490 | $1,114 | $1,020 | $966 |
| + Debt | $2,773 | $2,740 | $2,722 | $2,743 |
| Enterprise Value | $61,223 | $43,912 | $36,718 | $32,036 |
| Revenue | $1,249 | $774 | $594 | $593 |
| % Growth | 61.4% | 30.2% | 0.2% | – |
| Gross Profit | $1,052 | $631 | $523 | $490 |
| % Margin | 84.2% | 81.5% | 88% | 82.7% |
| EBITDA | $297 | $19 | $11 | -$141 |
| % Margin | 23.8% | 2.4% | 1.9% | -23.8% |
| Net Income | $251 | -$66 | -$57 | -$84 |
| % Margin | 20.1% | -8.6% | -9.7% | -14.1% |
| EPS Diluted | 1.84 | -0.51 | -0.44 | -0.65 |
| % Growth | 460.8% | -15.9% | 32.3% | – |
| Operating Cash Flow | $325 | $154 | -$118 | -$95 |
| Capital Expenditures | -$12 | -$14 | -$9 | -$9 |
| Free Cash Flow | $313 | $139 | -$127 | -$104 |